AKT1 and cancer: Consistently, our preliminary data that LY294002, an inhibitor of PI3K-Akt signaling pathway, significantly diminished ADAMTS1 activation in cancer cell-precocultured NAF, suggesting that PI3K-Akt signaling may mediate the initial step to down-regulate the binding of EZH2 to ADAMTS1 promoter (data not shown).